{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:06:47Z","timestamp":1789625207029,"version":"build-2803163510"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,4,16]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec id=\"s1\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In psoriatic arthritis (PsA), both psoriasis and musculoskeletal manifestations may impair Health-Related Quality of Life (HRQoL). Our objective was to explore the impact of the various disease manifestations and disease consequences, including psychosocial factors, on HRQoL in PsA patients treated in the biologic treatment era.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s2\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data collection in the 131 outpatient clinic PsA patients assessed included demographics, disease activity measures for both skin and musculoskeletal involvement and patient-reported outcome (PRO) measures, treatment and psychosocial burden. The skin dimension of quality of life was assessed by the Dermatology Life Quality Index (DLQI) and the overall HRQoL by the 15-Dimensional (15D) Questionnaire.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s3\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mean age was 51.9\u00a0years, PsA disease duration 8.6\u00a0years, 50.4% were men, 56.9% were employed\/working and 47.7% had \u22651 comorbidities. Prevalence of monotherapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) was 36.6% and with biologic DMARDs 12.2% and combination of both 22.9%. Mean DLQI was 3.3 and 15D 0.84. In adjusted analysis, not employed\/working, higher scores for fatigue, sleep disturbances, anxiety and depression, Modified Health Assessment Questionnaire and presence of comorbidities were independently associated with impaired HRQoL (lower 15D scores), whereas Psoriasis Area Severity Index (PASI) and DLQI were not. Younger age and higher Psoriatic Arthritis Disease Activity Score and PASI scores were independently associated with impaired skin quality of life (higher DLQI score).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s4\">\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our study highlights the negative impact the psychosocial burden, impaired physical function and comorbidities has on reduced HRQoL in PsA outpatients. Thus, to further improve HRQoL in PsA patients, not only physical concerns but also psychological concerns need to be addressed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001223","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T17:37:45Z","timestamp":1589477865000},"page":"e001223","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":38,"title":["Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9279-5191","authenticated-orcid":false,"given":"Glenn","family":"Haugeberg","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Dept. of Medicine, Sorlandet Hospital Kristiansand, Kristiansand, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-2840","authenticated-orcid":false,"given":"Brigitte","family":"Michelsen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital of Southern Norway Trust Kristiansand, Kristiansand, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[{"name":"UCSD, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"2025090313580050000_6.1.e001223.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090313580050000_6.1.e001223.2","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12771","article-title":"Psoriasis and suicidality: a review of the literature","volume":"32","author":"Liang","year":"2019","journal-title":"Dermatol Ther"},{"key":"2025090313580050000_6.1.e001223.3","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T"},{"key":"2025090313580050000_6.1.e001223.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200387"},{"key":"2025090313580050000_6.1.e001223.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-215003"},{"key":"2025090313580050000_6.1.e001223.6","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s10067-019-04446-z","article-title":"Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study","volume":"38","author":"Alten","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090313580050000_6.1.e001223.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160973"},{"key":"2025090313580050000_6.1.e001223.8","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002086"},{"key":"2025090313580050000_6.1.e001223.9","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026475531996"},{"key":"2025090313580050000_6.1.e001223.10","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-3211-7"},{"key":"2025090313580050000_6.1.e001223.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"2025090313580050000_6.1.e001223.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"2025090313580050000_6.1.e001223.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213286"},{"key":"2025090313580050000_6.1.e001223.14","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s11136-016-1321-7","article-title":"Health-related quality of life in patients with psoriasis: a systematic review of the European literature","volume":"25","author":"Obradors","year":"2016","journal-title":"Qual Life Res"},{"key":"2025090313580050000_6.1.e001223.15","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.122755"},{"key":"2025090313580050000_6.1.e001223.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160963"},{"key":"2025090313580050000_6.1.e001223.17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40744-018-0120-8","article-title":"Skin involvement in psoriatic arthritis worsens overall disease activity, patient-reported outcomes, and increases healthcare resource utilization: an observational, cross-sectional study","volume":"5","author":"de Vlam","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2025090313580050000_6.1.e001223.18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171406"},{"key":"2025090313580050000_6.1.e001223.19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/acr.23330","article-title":"Impact of disease severity, illness beliefs, and coping strategies on outcomes in psoriatic arthritis","volume":"70","author":"Howells","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313580050000_6.1.e001223.20","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s00296-018-4153-7","article-title":"Gender does not make a difference in \u201ccomposite psoriatic disease activity index (CPDAI)\u201d in patients with psoriatic arthritis","volume":"38","author":"Kenar","year":"2018","journal-title":"Rheumatol Int"},{"key":"2025090313580050000_6.1.e001223.21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/14397595.2016.1193105","article-title":"Gender specific differences in patients with psoriatic arthritis","volume":"27","author":"Nas","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2025090313580050000_6.1.e001223.22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313580050000_6.1.e001223.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242"},{"key":"2025090313580050000_6.1.e001223.24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00403-019-01906-z","article-title":"Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic patient survey of psoriasis and psoriatic arthritis (NORPAPP)","volume":"311","author":"Duvetorp","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"2025090313580050000_6.1.e001223.25","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/1756-185X.12505","article-title":"Sleep quality in patients with psoriatic arthritis","volume":"20","author":"Gezer","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2025090313580050000_6.1.e001223.26","doi-asserted-by":"crossref","unstructured":"Bavi\u00e8re W, Deprez X, Houvenagel E, et al. Association between comorbidities and quality of life in psoriatic arthritis: results from amulticentric cross-sectional study (PSAQUAL study). J Rheumatol 2020;47:369\u201376.","DOI":"10.3899\/jrheum.181471"},{"key":"2025090313580050000_6.1.e001223.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211284"},{"key":"2025090313580050000_6.1.e001223.28","doi-asserted-by":"crossref","unstructured":"Iannone F , Nivuori M , Fornaro M , et al. Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. Rheumatology (Oxford) 2019. [Epub ahead of print]doi: 10.1093\/rheumatology\/kez505","DOI":"10.1093\/rheumatology\/kez505"},{"key":"2025090313580050000_6.1.e001223.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210579"},{"key":"2025090313580050000_6.1.e001223.30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s12325-018-0866-y","article-title":"Real-world postmarketing study of the impact of adalimumab treatment on work productivity and activity impairment in patients with psoriatic arthritis","volume":"36","author":"Nakagawa","year":"2019","journal-title":"Adv Ther"},{"key":"2025090313580050000_6.1.e001223.31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","article-title":"Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis","volume":"21","author":"Gladman","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090313580050000_6.1.e001223.32","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/acr.23000","article-title":"Ustekinumab treatment and improvement of physical function and health-related quality of life in patients with psoriatic arthritis","volume":"68","author":"Rahman","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313580050000_6.1.e001223.33","doi-asserted-by":"crossref","unstructured":"Mourad A, Gniadecki R. Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: asystematic review and metaanalysis. J Rheumatol 2020;47:59\u201365.","DOI":"10.3899\/jrheum.180797"},{"key":"2025090313580050000_6.1.e001223.34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41927-018-0030-y","article-title":"Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients\u2019 health-related quality of life and productivity","volume":"2","author":"Coates","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2025090313580050000_6.1.e001223.35","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000808","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL beyond","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2025090313580050000_6.1.e001223.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211998"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:58:09Z","timestamp":1756933089000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,14]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/rmdopen-2020-001223"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001223","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}